The purpose of this review is to describe the effects of mechanical circulatory support (MCS) on changes in kidney function and their relationship with mortality, with an additional focus on the evaluation and management of both preimplant and post-MCS renal dysfunction.
INTRODUCTION
Left ventricular assist devices (LVADs) have become a fundamental treatment of advanced heart failure that is increasing exponentially [1] . The dramatic survival benefit with current LVADs has led to a shift in goals of care from simply surviving implantation to decreasing long-term morbidity by improving and maintaining end-organ function, including kidney function [2, 3] . The currently used LVADs provide blood flow to the body via a rotary pump, creating a continuous-flow circulatory system with reduced or absent pulsatility. Advantages of current LVADs include lack of valves and fewer moving parts, translating into improved survival and fewer adverse events than had plagued earlier pulsatile devices [2, 3] . As a result, fully pulsatile LVADs are no longer implanted and both current and newly developed LVADs use continuous-flow technology, underscoring the vital importance of determining their effects on the kidneys. Furthermore, renal dysfunction is common in patients with advanced heart failure referred for mechanical circulatory support (MCS). Following MCS, these patients have the potential to achieve marked improvements in kidney function from the increased cardiac output,
PRE-MECHANICAL CIRCULATORY SUPPORT RENAL FUNCTION AND PROGNOSIS
In patients with advanced heart failure referred for MCS, renal dysfunction is highly prevalent; the mean estimated glomerular filtration rate (eGFR) prior to LVAD implantation is 60.9 AE 34.7 ml/min/ 1.73 m 2 [4 && ]. Importantly, renal dysfunction is one of the most powerful mortality indicators in all patients with heart failure, outperforming traditional metrics of disease severity such as ejection fraction and functional class [5] . Therefore, it is not surprising that pre-MCS renal function is powerfully linked to post-MCS survival [6] [7] [8] . The HeartMate II Risk Score, developed from the Heart-Mate II clinical trial (Thoratec, Pleasanton, CA, USA), is the most commonly used predictor model in the current era of continuous-flow devices. Baseline creatinine is one of the stronger components of the score; for every mg/dl increase in creatinine, the odds of death at 90 days postimplant doubles [6] . When baseline renal dysfunction is categorized using both eGFR and blood urea nitrogen (BUN) levels, nearly 25% of patients with severe renal dysfunction die within 3 months ( Fig. 1) [8] . The mortality disadvantage associated with preimplant dialysis is even more sobering, with mortality rates in excess of 30% at 3 months, a rate that increases to 50% in Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) risk profile 1 -'Critical Cardiogenic Shock' patients [8] .
EARLY CHANGES IN RENAL FUNCTION AFTER MECHANICAL CIRCULATORY SUPPORT AND PROGNOSIS
Although baseline renal dysfunction portends a poor prognosis following MCS, the majority of patients actually experience significant improvement in renal function (IRF) within the first month, with an average eGFR increase of 25 ml/min/1.73 m 2 [4 && ,8-13,14 & ,15-19] . In an analysis of 3363 patients, 60% of patients improved their eGFR by 20%, 40% of patients improved by more than 50%, and 20% improved by greater than 100% 1 month after LVAD, regardless of device strategy ( Fig. 2a ) or disease severity denoted by INTERMACS class (Fig. 2b) [4 && ]. Patients with moderate to severe renal
KEY POINTS
Renal dysfunction is common in patients referred for MCS and is one of the strongest risk factors for both early and late adverse outcomes.
Although there are currently no diagnostic tests to definitively distinguish irreversible forms of renal dysfunction from likely reversible forms of renal dysfunction (i.e. heart failure-induced renal dysfunction) in patients referred for MCS, elevated markers indicative of increased neurohormonal activation and venous congestion, pathophysiologic factors involved in heart failure-induced renal dysfunction, may provide some discrimination ability.
Although most patients, including those with renal dysfunction, experience early improvement in renal function with MCS, this improvement is often transient, with subsequent recurrence of renal dysfunction with longer durations of MCS.
Venous congestion, right ventricular dysfunction, and reduced pulsatility are potential mechanisms involved in resurgence of renal dysfunction following MCS.
Although there is no clearly preferred method of renal replacement therapy in MCS, peritoneal dialysis may be preferred as it provides sustained daily UF, fewer volume-related preload issues, home accessibility, and reduced cost. Actuarial curves show survival stratified by severity of preimplant renal dysfunction. BIVAD, biventricular assist devices; BTT, bridge to transplant; BUN, blood urea nitrogen; DT, destination therapy; GFR, glomerular filtration rate; LVAD, left ventricular assist device. Reproduced from [8] .
dysfunction also exhibit marked early IRF; Hasin and colleagues noted nearly 75% of patients with stage 3 chronic kidney disease improved their eGFR to above 60 ml/min/1.73 m 2 by 1 month [10] . Similar findings were reported in INTERMACS, as the mean eGFR at 1-month in patients presenting with renal dysfunction exceeded 80 ml/min/1.73 m 2 [4 && ].
As much of the renal dysfunction observed in patients referred for MCS is likely heart failure induced, the substantial IRF observed is not astonishing, particularly given that many of the factors thought responsible for heart failure-induced renal dysfunction, such as increased neurohormonal activation, venous congestion, and reduced perfusion, often resolve with MCS [5, 20, 21] . Reductions of renin and aldosterone in the first few weeks of MCS, coupled with the improvement in the hemodynamic perturbations of advanced heart failure, may partially account for early IRF [22, 23] . Jacobs et al. [14 & ] demonstrated that decreases in creatinine, natriuretic peptides, and diuretic dose following MCS occurred in parallel, supporting a role for decreased congestion as a driver of IRF.
Despite the overwhelming frequency and magnitude of IRF, patients undergoing MCS display many risk factors for acute kidney injury (AKI), namely, cardiogenic shock, baseline renal dysfunction, and exposure to cardiopulmonary bypass, and as a result, AKI is not uncommon [1] [2] [3] [24] [25] [26] [27] [28] [29] [30] [31] . Depending on the AKI definition employed and the population studied, the incidence of post-MCS AKI is between 5 and 33% ( ]. In a recent study by Naik et al., patients with AKI were three times more likely to die within 30 days [31] . AKI also negatively impacts ICU and hospital lengths of stay [26, 31] . Notably, patients with MCS with AKI requiring dialysis are less likely to undergo cardiac transplantation (53 vs. 84%), the definitive therapy for advanced heart failure [32] .
Although the relationship between post-MCS AKI and prognosis is easily comprehensible, the relationship between IRF and prognosis is perplexing. We reported that the relationship between changes in eGFR following MCS appears to be Ushaped: patients with the largest improvements in renal function experience the equivalent increased risk for mortality as those patients with the most significant AKI, independent of baseline renal dysfunction, or patient and device characteristics ( ]. A similar association between IRF and mortality has been reported in patients with heart failure [33] . One potential explanation for these counterintuitive findings is that substantial IRF is serving as a marker of disease severity: the greater the magnitude of eGFR improvement, the more significant the heart failure-induced renal dysfunction prior to MCS, which is indicative of a more severe form of heart failure. Further research to understand this paradoxical relationship is ongoing.
THE IMPACT OF RENAL DYSFUNCTION ON PATIENT SELECTION FOR MECHANICAL CIRCULATORY SUPPORT
In light of the relationship between renal dysfunction and mortality, appropriate patient selection for MCS relies heavily on determining renal function before implantation. Although both the American Heart Association and International Society of Heart Lung Transplantation guidelines recommend renal function assessment, the manner in which it is assessed is left to the discretion of the treating physician [34, 35] . The most commonly used metric of renal function is serum creatinine, which has significant shortcomings. Because of the exponential relationship between creatinine and GFR, an absolute change in creatinine can represent a small or large fluctuation in renal function depending on the baseline creatinine ( Fig. 4a ) [36] . As a result, equations have been developed to better estimate GFR that incorporate creatinine but also include variables like age, sex, weight, or race that minimize the inadequacies of using creatinine alone. One important consideration in the MCS population is the high prevalence of cardiac cachexia and subsequent decreased creatinine production, which can lead to overestimation of GFR ( Fig. 4b ) [37] . Equations for GFR that incorporate cystatin C, a cysteine protease that is not determined by muscle mass, appear to minimize the bias associated with solely creatinine-based methods, increase renal dysfunction detection in heart failure, provide a stronger relationship with mortality, and most accurately correlate with direct GFR measurements [38, 39] . Although all creatinine and cystatin C-based eGFR equations have been validated in patients with stable heart failure, the most accurate method for use in MCS is unknown.
Regardless of how pre-MCS renal dysfunction is determined, renal dysfunction deemed 'irreversible' is an absolute contraindication to durable MCS [35] . Unfortunately, identification of patients with reversible forms of renal dysfunction, who are therefore likely to experience IRF with MCS, is challenging. Multiple studies have shown that patients with more severe renal dysfunction possess the greatest potential for IRF, whereas Imamura et al. [10, 19, 40] reported that preimplant creatinine is the best predictor of maintenance of renal function post-MCS. Utilizing baseline renal dysfunction as a primary indicator of likely post-MCS IRF is dangerous, given that not all renal dysfunction in patients referred for MCS is heart failure induced. Patients with heart failure have comorbid conditions such as diabetes and hypertension, which lead to nephron loss that is often irreversible [41] . In fact, patients with diabetes are less likely to experience post-MCS IRF [18] . Although there are currently no diagnostic tests to definitively distinguish irreversible forms of renal dysfunction from likely reversible forms of renal dysfunction (i.e. heart failure-induced renal dysfunction), elevated markers indicative of increased neurohormonal activation and venous congestion, pathophysiologic factors involved in heart failureinduced renal dysfunction, may provide some discrimination ability. We demonstrated in patients with heart failure that an admission BUN/Cr was independently associated with IRF during the hospitalization [odds ratio (OR) ¼ 1.7; 95% confidence interval (CI), 1.2-2.4; P ¼ 0.007] [42] . The same group also described that patients with severe renal dysfunction (eGFR 45 ml/min/1.73 m 2 ) and laboratory evidence of hepatic congestion during acute decompensated heart failure were five times more likely to experience IRF with return to compensation [43] . Interestingly, both an elevated preimplant BUN/Cr and preimplant congestive hepatopathy are also significantly associated with IRF 1 month following MCS [10, 43, 44] . Finally, elevated baseline markers of kidney injury may portend inferior post-MCS renal outcomes: Pronschinske et al. [45 && ] highlighted that increased levels of serum neutrophil gelatinaseassociated lipocalin (NGAL) before LVAD were associated with a lack of post-MCS IRF. One important caveat for these and other retrospective studies of renal dysfunction in MCS is the possibility of selection bias, given all patients with significant renal dysfunction who undergo MCS are believed to have reversible renal dysfunction or they would not receive a device.
Appropriately selected patients with renal dysfunction may possess the potential for IRF with MCS; however, these benefits are contingent upon avoiding postoperative AKI, for which this group of patients is at increased risk. Although many of the most ubiquitous risk factors for AKI are not modifiable (i.e. low ejection fraction, cardiac surgery, increased age), there is room for patient optimization before MCS that may minimize AKI [46] . In addition to their significantly increased mortality, INTERMACS profile 1 patients have an incidence of post-MCS AKI requiring dialysis that approaches 30%, providing support for improved renal outcomes with earlier implantation [47, 48] . Elevated central venous pressure is also strongly associated with post-MCS AKI, stressing the importance of management of volume status and right ventricular (RV) dysfunction prior to surgery [26] . Finally, one of the most common questions in pre-MCS patients with renal dysfunction is whether to discontinue angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) before surgery. Coca and colleagues examined the renal effects of continuing these medications on the day of surgery compared with their discontinuation in over 1500 patients deemed high risk for AKI who underwent cardiac surgery. Patients who received ACE inhibitors and ARBs on the day of surgery were more likely to experience small increases in creatinine (a known effect of these drugs), but their incidence of renal injury detected with kidney injury biomarkers was no different than in those patients who discontinued these medications, nor was there a difference in length of stay [49] . These results, coupled with emerging data suggesting these drugs may be reno-protective in the event of ischemic injury, provide support for at least considering continuation of these medications before MCS [50] .
THE LONG-TERM TRAJECTORY OF RENAL FUNCTION WITH MECHANICAL CIRCULATORY SUPPORT AND PROGNOSIS
The first weeks following MCS are characterized by impressive improvements in kidney function, whereas the following months are notable for subsequent declines in eGFR that have been reported in multiple studies [ & ,52]. In over 3000 patients in INTERMACS, more than one third of patients experienced more than 20% decline in eGFR and one fifth of patients experienced more than 30% decline in eGFR from 1 to 3 months [4 && ]. This rate of eGFR decline far surpasses the normal decline of aging and that of progressive diabetic kidney disease [53, 54] . Notably, at 1 year post MCS, the median improvement in eGFR from baseline was only 2.6 ml/min/1.73 m 2 above the pre-MCS level [4 && ]. This pattern of continued decline in eGFR subsequent to a peak in function at 1 month persisted across subgroups regardless of device strategy ( Fig. 2a ) or disease severity (Fig. 2b) . To date, this marked resurgence of renal dysfunction is unexplained, but of clinical importance, as it is associated with a two-fold increase in mortality [4 && ]. Patients with pre-MCS renal dysfunction also display a renal function pattern of marked IRF followed by decline in eGFR; however, despite this decline, their eGFR at 1 year remained slightly above preimplant levels [4 && ,51 & ]. Perhaps the most significant observation regarding these late declines in eGFR is that they appear to be most prevalent in those patients who experience at least 50% IRF during the first month of MCS [4 && ]. These results suggest that patients who experience the greatest renal benefits from MCS are unable to maintain them. The same trend holds true in patients with pre-MCS renal dysfunction with perhaps more dire implications. For example, if a driving force for MCS in a given patient is to improve end-organ function for purposes of cardiac transplantation, although early improvement may be achieved, it may not be maintained long enough for that desired outcome. Furthermore, as the number of patients on long-term support grows exponentially and simultaneously with device longevity, continued maintenance of renal function will be essential.
MANAGEMENT OF RENAL DYSFUNCTION IN THE LONG TERM
There are a multitude of potential mechanisms involved with renal dysfunction during chronic MCS, the management of which may lead to IRF or counteract the reported later decrements in eGFR. Many of the data available are either generated from single-center MCS experience or extrapolated from the heart failure literature on cardiorenal dysfunction, as there have been no prospective studies aimed at either characterizing or treating changes in eGFR with MCS.
Persistent venous congestion
Venous congestion is one of the principal mechanisms believed to be partially responsible for cardiorenal dysfunction in heart failure. In animals, partial renal vein occlusion produces immediate decrements in renal blood flow, GFR, and sodium excretion that subsequently return to normal with relief of the increased venous pressure [55] . Patients with heart failure who are admitted with decompensation with multiple markers of increased congestion are significantly more likely to experience IRF with diuresis and return to compensation, supporting a role for venous congestion in heart failureinduced renal dysfunction [56] . Furthermore, even when adequate decongestion as assessed by natriuretic peptides leads to the opposite effect (worsening in kidney function), there is no associated mortality increase [57] . These results beg the question as to whether some of the observed post-MCS renal dysfunction may be related to inadequate decongestion, particularly given its associated mortality disadvantage. Therefore, there may be utility in aggressive decongestion potentially utilizing serial brain natriuretic peptide (BNP) levels in patients with MCS. Although Hellman et al. [58 && ] reported benefits of a similar approach on reducing length of stay post MCS, the effects of this strategy on renal outcomes have yet to be determined.
Right ventricular dysfunction
LVADs successfully restore left ventricle function and cardiac output, but appropriate LVAD function is dependent upon the preload delivered by the RV. As a result, RV dysfunction can negatively impact cardiac output, which in turn may have downstream effects on GFR. However, a more likely scenario is that the venous congestion induced by RV dysfunction impairs post-MCS renal function. Although there have been no studies of the impact of RV dysfunction on renal dysfunction in patients with MCS, in the heart failure population, an elevated admission central venous pressure (CVP)/ pulmonary capillary wedge pressure (PCWP) ratio is significantly associated with a lower admission eGFR [59] . Interestingly, an elevated pre-MCS CVP/PCWP ratio is also a powerful predictor of post-MCS RV failure, strengthening the potential relationship between RV dysfunction in MCS and renal dysfunction [60] .
The lack of pulsatility
One potential explanation for the late deterioration in eGFR may be that the device is injuring the kidney. In animals, early physiology experimentation revealed that pulse pressure and urine flow are tightly correlated and that continuous flow reduces GFR and renal blood flow compared with pulsatile flow [61, 62] . Dogs exposed to pulsatile flow in the right renal artery and continuous flow in the left renal artery developed increased local renin production restricted to the kidney exposed to continuous flow [63] . In calves implanted with current MCS devices, continuous flow led to dramatic upregulation of the local renin-angiotensin-aldosterone system, kidney smooth muscle cell hypertrophy and periarteritis [64] . These and other studies suggest that a pulsatile-flow environment enhances kidney structure and function.
Although the long-term effects of continuous flow (CF) on renal physiology and function are poorly understood in humans, more data are emerging. In patients with heart failure, CF-LVADs only minimally reduce systemic renin and aldosterone compared with pulsatile devices [22] . Cornwell et al. showed that increasing pulsatility in 13 CF-LVAD patients led to decreases in sympathetic nervous activity, which may have downstream renal benefits [65 && ]. Our group has demonstrated increasing levels of biomarkers with CF-LVAD support, indicative of ongoing kidney injury and activation of the local renin-angiotensin system despite early IRF [66] . Although these data suggest plausible mechanisms for potential detrimental renal effects of continuous flow, additional research is needed both to substantiate the findings and to investigate whether changes in medical or device strategies can mitigate the adverse renal outcomes.
Heart transplantation as bailout
Although improvements in MCS technology have led to similar 1-year survival of greater than 90%, heart transplantation remains the heart failure therapy with the greatest longevity [1, 67] . In patients implanted as bridge to transplantation (BTT) at centers without excessive wait times, transplant provides a bailout in the event of LVADrelated complications, particularly given that in general, posttransplant survival in patients on MCS is analogous to those on inotropes [68 & ]. Still, pretransplant renal dysfunction is associated with decreased graft survival, and in patients bridged with MCS before transplant, it is the pretransplant eGFR, not the pre-MCS eGFR, that dictates survival [19, 69] . More importantly, MCS appears to modify the effect of renal dysfunction on posttransplant outcomes, such that patients who undergo heart transplant with an eGFR < 45 ml/min/1.73 m 2 on MCS have the worst graft survival [68 & ]. These results have significant implications when evaluating patients with heart failure with renal dysfunction for advanced therapies. Although MCS can lead to IRF in a patient with preimplant renal dysfunction, that is significant enough to make him/her into a good heart transplant candidate; if that patient continues on MCS for 6-12 months, their eGFR may decline back toward pre-MCS levels, thereby eliminating some of the posttransplant survival benefit for which MCS was initially performed. As a result, the management of renal function after MCS is paramount for both BTT and destination patients.
WHEN RENAL REPLACEMENT THERAPY CANNOT BE AVOIDED: DIALYSIS CONSIDERATIONS IN MECHANICAL CIRCULATORY SUPPORT
In AKI following MCS, RRT is often required. Continuous venovenous hemodialysis can be performed in the ICU by nurses with specialized training and utilizing invasive hemodynamic monitoring. Hemodialysis with ultrafiltration may be complicated by hypotension and hemodynamic instability; inadequate preload can lead to suction of the ventricular septum and hemodynamic compromise [70 & ]. As the MCS patient becomes hemodynamically stable, transition to intermittent hemodialysis can be successful. The pulsatility index on a Heart-Mate II device and the variability on a Heartware device can be used as surrogates for volume status and aid in determination of goal ultrafiltration [71] . Importantly, ability to undergo hemodialysis successfully is often a hurdle to ICU discharge.
Discharge planning for hemodialysis can be complicated by limited availability of outpatient centers that accept patients with MCS. With training and ongoing involvement from the implanting center, outpatient hemodialysis can be successfully performed. Quader et al. reported on 10 patients requiring RRT who underwent 281 hemodialysis sessions with only 5.3% requiring interruption.
The most frequent causes of interruption were hypotension and arrhythmias, yet there were no serious adverse events or deaths [70 & ]. Another difficulty of hemodialysis is assessment of blood pressure in patients with CF-LVADs. The pulse pressure is reduced; therefore, automated cuff recordings may be difficult to obtain, albeit accurate [72] . Doppler ultrasonography is often used, which closely approximates systolic blood pressure. Monitors with oscillometric slow-deflation technology like the Terumo (Somerset, NJ, USA) allow more precise determinations of systolic and diastolic blood pressures and have been shown to correlate with arterial line pressures in patients with LVAD [73] . Current guidelines recommend maintaining a mean arterial pressure between 70 and 80 mmHg [71] .
Careful consideration of hemodialysis access is required, as systemic bacteremia can lead to chronic MCS infection. Short-term catheters should be exchanged for tunneled catheters at the earliest opportunity. Aortic valve grafts have been successful in patients with MCS and are preferred over fistulas because of concerns regarding lack of maturation on continuous flow [71] . Alternatively, peritoneal dialysis spares the patient from infection risk, as peritonitis rarely leads to bacteremia [74 & ]. Peritoneal dialysis may be preferred, as it provides sustained daily ultrafiltration, fewer volume-related preload issues, home accessibility and reduced cost [75] . Peritoneal dialysis is feasible in patients with MCS if the surgeon places the catheter clear of the driveline site. One important consideration regarding peritoneal dialysis is the albumin losses, which can have significant effects on malnourished patients [74 & ]. Currently, there is no clearly favored approach to RRT in MCS, but for RRT to be successful, collaboration among hemodialysis centers, nephrologists and heart failure cardiologists is imperative.
CONCLUSION
Renal dysfunction is common in patients referred for MCS and is one of the strongest risk factors for adverse outcomes. Although these patients experience an increased risk for postoperative AKI, early IRF is very common. Unfortunately, these early improvements are transient, and renal dysfunction recurs frequently with prolonged MCS. As both the early IRF and delayed worsening in eGFR are associated with increased mortality, additional research is critical to both improve our understanding of the potential mechanisms and identify treatment strategies for a population that only continues to grow exponentially.
